These results suggested that MSC treatment not only improved the clinical outcomes of COVID-19 patients but also reduced the levels of CRP, proinflammatory cytokines, and NETs, as well as promoted the production of SARS-CoV-2-specific antibodies and maintained their levels for a longer period compared with placebo treatment. Here, CRP is linked to COVID-19.